NUWE · Nuwellis, Inc. · Exempt Offerings
$3.50
-0.31 (-8.14%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Nov 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions, including continued operating losses, negative cash flows from operations, an accumulated deficit of $327.7 million, and the need for additional capital to fund ongoing operations and growth initiatives (including the integration of Rendiatech Ltd., an Israeli company (“Rendiatech”) following the Company’s acquisition), raise substantial doubt about the Company’s ability to continue as a going concern for at least twelve months from the date these financial statements are issued. While management’s plans, including recent financing activities, cost discipline initiatives, and contingency measures, are intended to address these conditions, such plans do not alleviate the substantial doubt.”View the 10-Q filed Nov 12, 2026
Market Cap
$2.06M
Shares
540,912
Volume · Nov 20
4835
Avg daily vol (18 sessions)
2.34M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2024-11-20 | New | Other Health Care | $3,848,286 | $3,848,286 | 06b |
| 2024-09-04 | New | Other Health Care | Indefinite | $0 | 06b |
| 2024-08-02 | New | Other Health Care | Indefinite | $0 | 06b |
| 2023-06-26 | New | Biotechnology | Indefinite | $0 | 06b |
| 2020-05-07 | New | Biotechnology | $1,699,998 | $1,699,998 | 06b |
| 2020-04-08 | New | Biotechnology | $2,226,519 | $2,226,519 | 06b |
| 2020-03-30 | New | Biotechnology | $1,248,418 | $1,248,418 | 06b |
Showing 1–7 of 7 filings
Key facts
CIK
1506492
CUSIP
67113Y884
13F (30d)
15 filings
12 filers
Visit website
Investor relations